Biophytis S.A. (BPTSY)

OTCMKTS: BPTSY · Delayed Price · USD
5.82
0.00 (0.00%)
Jul 12, 2024, 2:51 PM EDT - Market open
Market Cap 1.67M
Revenue (ttm) n/a
Net Income (ttm) -18.92M
Shares Out 286.50K
EPS (ttm) -130.98
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 17
Open 5.82
Previous Close 5.82
Day's Range n/a
52-Week Range 5.44 - 142.00
Beta n/a
Analysts n/a
Price Target n/a
Earnings Date n/a

About BPTSY

Biophytis S.A., a clinical-stage biotechnology company, focuses on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Its therapeutics targets and activates key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses, including inflammatory, oxidative, metabolic, and viral stresses that lead to age-related diseases. The company's lead drug candidate is BIO101, an ora... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2006
Employees 22
Stock Exchange OTCMKTS
Ticker Symbol BPTSY
Full Company Profile

Financial Performance

Financial numbers in EUR Financial Statements

News

Biophytis Obtains IND Approval from the FDA to Start its Phase 2 OBA Study in Obesity

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 11, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...

4 days ago - Accesswire

Biophytis Presented its Phase 2-3 COVA Study Results in Severe Forms of Covid-19 at the WCID in Paris

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 1, 2024 / Biophytis SA (Euronext Growth Paris : ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the de...

14 days ago - Accesswire

Biophytis grants Blanver Exclusive Rights to BIO101 in Latin America in Deal Valued at up to €108 Million

Biophytis to receive upfront and milestones payments for a total amount up to €108 million, as well as double-digit royaltieson future sales of the product Agreement covers commercialization of BIO101...

25 days ago - Accesswire

Biophytis Extends Its Contract With Atlas to Secure Financing for Its Business Activities

Important note: Biophytis has set up financing in the form of Bonds redeemable in cash and in new and existing shares (ORNANE) with the company Atlas, which, after having received the shares resulting...

25 days ago - Accesswire

Biophytis Announces the Successful Industrial Transfer of BIO101 (20-hydroxyecdysone) Production by its Service Provider Seqens

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / June 12, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...

4 weeks ago - Accesswire

Biophytis Announces Filing of an IND Application with the US FDA for its Phase 2 Study in Obesity

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / June 10, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the dev...

5 weeks ago - Accesswire

Biophytis Announces the Design of its Phase 2 OBA Clinical Study in Obesity

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / May 14, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the deve...

2 months ago - Accesswire

Biophytis is Deploying its Partnership Strategy in Obesity

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 29, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in the de...

2 months ago - Accesswire

Biophytis Announces Transfer of ADSs to OTC Market

ADSs delisted from Nasdaq, which will result in meaningful savings ADSs transferred to OTC Pink market; Company will apply to trade on OTCQB market Biophytis remains listed on Euronext Growth Paris as...

2 months ago - Accesswire

Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 19, 2024 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speci...

3 months ago - Accesswire

Biophytis Announces New Scientific Advisory Board for its Phase 2 OBA Clinical Study in Obesity

IND to be filed with the FDA in the coming weeks PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 18, 2024 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company")...

3 months ago - Accesswire

Biophytis Announces Its 2023 Financial Results and Provides an Update on Its Business Activities

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (NASDAQ:BPTS), (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company special...

3 months ago - Accesswire

Biophytis launches OBA phase 2 clinical study in obesity with BIO101 (20-hydroxyecdysone)

Promising preclinical results obtained in obesity support the OBA Phase 2 clinical study expected to start mid-2024 PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 8, 2024 / Biophytis SA (Nasdaq:...

3 months ago - Accesswire

Results of the Combined General Meeting on April 2, 2024

All resolutions presented by the Company have been adopted PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / April 4, 2024 / Biophytis SA (NASDAQ:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis" or the ...

3 months ago - Accesswire

Biophytis Presented its Phase 3 Protocol in the Treatment of Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / March 22, 2024 / Biophytis SA (Nasdaq:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speciali...

4 months ago - Accesswire

Biophytis Announces Receipt of Nasdaq Notice

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / November 17, 2023 / Biophytis SA (NASDAQ:BPTS)(Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company speci...

8 months ago - Accesswire

Biophytis and Innovation Solutions Pharma Sign a Partnership Agreement to Accelerate Market Access for Sarconeos (BIO101) in Brazil

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 30,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the de...

9 months ago - Accesswire

Biophytis Receives Notice of Delisting From NASDAQ and Announces It Will Request a Hearing Before the NASDAQ Hearings Panel

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / October 27, 2023 / Biophytis SA (NASDAQCM:BPTS),(Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the d...

9 months ago - Accesswire

Biophytis Releases Its Half-Yearly Accounts as of 30 June 2023 and Provides an Update on Its Operations

Start of industrial development of Sarconeos (BIO101) with a view to market access in severe forms of Covid-19 (COVA) Approvals to start the Phase 3 trial in the United States and Belgium in sarcopeni...

10 months ago - Accesswire

Biophytis and Skyepharma sign a Partnership Agreement for the Production of Sarconeos (BIO101)

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 25, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...

10 months ago - Accesswire

Biophytis Provides an Update on its Early Access Programs for Sarconeos (BIO101) in the Treatment of Severe Forms of COVID-19

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 19, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...

10 months ago - Accesswire

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the d...

10 months ago - Accesswire

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the ...

11 months ago - Accesswire

Biophytis to Participate at the H.C. Wainwright 25th Global Investment Conference in New York

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 4, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company sp...

11 months ago - Accesswire

Biophytis Announces Next Regulatory Steps in Europe and the United States for its COVA Project

PARIS FRANCE and CAMBRIDGE, MA / ACCESSWIRE / August 16, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), ("Biophytis"), a clinical-stage biotechnology company specialized in the dev...

11 months ago - Accesswire